Trial Profile
A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Dexamethasone
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms COMRADE-B
- Sponsors Novartis
- 03 Jun 2014 New source identified and integrated, European Clinical Trials Database record (EudraCT2011-001019-30).
- 03 Jun 2014 New trial record
- 12 May 2014 Primary endpoint 'Best-corrected-visual-acuity' has been met according to the Novartis media release.